Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Department of Otolaryngology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
JCI Insight. 2020 Feb 13;5(3):130845. doi: 10.1172/jci.insight.130845.
Interleukin-1β (IL-1β) is a key proinflammatory cytokine involved in the progression of many autoinflammatory and autoimmune diseases, including autoimmune inner ear disease (AIED). IL-1β inhibition has been shown to result in clinical hearing improvement in a small cohort of corticosteroid-resistant patients with AIED. Canonical processing of pro-IL-1β by caspase-1 generates an active 17-kDa fragment, capable of instigating a proinflammatory microenvironment. However, in response to LPS, PBMCs from patients with AIED uniquely express a 28-kDa IL-1β fragment, as compared with PBMCs from control subjects. We synthesized and compared the biologic activity of the 28-kDa fragment to the 17-kDa IL-1β product and the pro-IL-1 31-kDa protein. The 28-kDa IL-1β fragment induces IL-6, TNF-α, and CCL3 in PBMCs. Uniquely, only caspase-7 treatment showed a dose- and time-dependent increase in 28-kDa band generation. Mass spectrometry confirmed the putative caspase-7 cleavage site of pro-IL-1β, which was used to generate the 28-kDa fragment used for PBMC stimulation studies. Collectively, these results provide insight into the function of a poorly understood, processed 28-kDa form of IL-1β in patients with AIED that is uniquely generated by caspase-7 and is capable of activating further downstream proinflammatory cytokines. Further investigation may provide novel pharmacologic targets for the treatment of this rare disease.
白细胞介素-1β(IL-1β)是一种关键的促炎细胞因子,参与许多自身炎症性和自身免疫性疾病的进展,包括自身免疫性内耳疾病(AIED)。IL-1β抑制已被证明可导致小部分皮质类固醇耐药的 AIED 患者的临床听力改善。前体 IL-1β 经半胱天冬酶-1的经典加工生成具有活性的 17kDa 片段,能够引发促炎微环境。然而,与对照相比,来自 AIED 患者的 PBMC 对 LPS 的反应独特地表达 28kDa 的 IL-1β 片段。我们合成并比较了 28kDa 片段与 17kDa IL-1β 产物和前体 IL-1β 31kDa 蛋白的生物学活性。28kDa IL-1β 片段可诱导 PBMC 中 IL-6、TNF-α 和 CCL3 的表达。独特的是,只有半胱天冬酶-7 处理显示出剂量和时间依赖性地增加 28kDa 带的生成。质谱证实了前体 IL-1β 的假定半胱天冬酶-7 切割位点,该位点用于生成用于 PBMC 刺激研究的 28kDa 片段。总之,这些结果为 AIED 患者中一种理解甚少的加工后 28kDa 形式的 IL-1β 的功能提供了深入了解,该形式仅由半胱天冬酶-7 产生,并且能够激活进一步的下游促炎细胞因子。进一步的研究可能为这种罕见疾病的治疗提供新的药理学靶点。